



Announcement

The Egyptian International Pharmaceuticals Industries Company (EIPICO)

Dr. Ahmed Saied Kelani, Chairman of the Board of Directors and Managing Director, has the honor to invite the esteemed shareholders to attend the extraordinary general assembly scheduled to be held at 12:00 PM on Saturday, February 18, 2023 at the company's main headquarters in 10th of Ramadan City, Industrial Zone B1. The meeting is to consider:

1. Increasing the company's issued capital from EGP 991,705,000 to EGP 1,140,460,750, an increase of EGP 148,755,750 as 15% of the current capital, distributed to 14,875,575 shares based on a fair value of EGP 54.72 per share according to the independent financial advisor (Eagle Consulting Financial Advisors), with a nominal value of EGP 10 per share, plus an additional premium of EGP 44.72 per share through a cash subscription for existing shareholders, with the subscription rights traded separately from the original shares, and a presentation of the feasibility study related to the increase and use of the funds generated, based on the approval of the Financial Regulatory Authority issued on January 5, 2023.
2. Delegate the Chairman of the Board of Directors and Managing Director, or a representative, to submit the necessary applications to governmental bodies to proceed with inviting existing shareholders to participate in the capital increase and to liaison with said bodies to establish the dates of the subscription period and the separate trading of subscription rights.
3. Amending articles 6 and 7 of the company's articles of association in light of the extraordinary general assembly's approval of an increase in the company's capital and in light of the explanations provided in the subscription of the increased shares and empowering the Board of Directors to draft the amended text of articles 6 and 7 based on the subscription and empowering the Chairman of the Board of Directors or those delegated by him to take the necessary measures to amend the company's articles of association before the competent authorities and to make any amendments deemed necessary by these authorities in accordance with the organized rules.

We would like to bring the following to the attention of our shareholders:

- Each shareholder entitled to ten shares can attend the general assembly in person or by proxy, and the proxy must be one of the shareholders and not a member of the Board of Directors, and the power of attorney must be authenticated and in all cases, the number of shares held by the proxy must not exceed 10% of the capital.
- Shareholders who wish to attend the extraordinary general meeting should go to the Misr for Central Clearing, Depository and Registry (MCDR) company to obtain a certificate indicating the freezing of their balance until the end of the meeting, at least three days before the meeting.
- Any questions regarding the agenda must be submitted in writing to the company's headquarters either by hand or registered mail at least three days before the meeting.

Note: Children are not allowed to attend.

Best regards,



Press release

About the Egyptian International Company for Pharmaceutical Industries – EIPICO

EIPICO was established in the 10th of Ramadan City in 1980 with a capital of 7 million Egyptian pounds, which has now been increased to 1500 million pounds, as an Egyptian joint stock company operating in accordance with the investment law and has been listed on the Egyptian Stock Exchange since 1995 under the code (**PHAR.CA**). EIPICO started production in 1985 as a leading company in the pharmaceutical industry in Egypt according to the rules of good manufacturing practices.

EIPICO has two factories built on an area of 120,000 square meters, with 9 sterile areas being the largest and most advanced in Egypt and the Middle East and North Africa region and the first center for biotechnology and genetic engineering research for the manufacture of biological preparations.

EIPICO manufactures more than 400 pharmaceutical products covering 25 therapeutic groups. EIPICO ranks first in the Egyptian ophthalmology market by units. It is also the leading Egyptian pharmaceutical export company, as its products are exported to more than 69 countries around the world with a market share of 23% Total Egyptian pharmaceutical exports

For more information, please visit our official website <https://eipico.com.eg>

To communicate:

Investor Relations

Tenth of Ramadan - First Industrial Zone - B1

Tel: 055499199

Fax: 055499306

a.elmoraly@eipico.net

###